Gilead Sciences agreed to buy Interius BioTherapeutics, a privately held biotechnology company developing in-vivo CAR therapeutics, for $350 million.
Gilead on Thursday said the deal complements the cell-therapy expertise of its Kite unit by incorporating Interius's integrating in-vivo platform.
The Foster City, Calif., biopharmaceutical company said this approach enables the generation of CAR T-cells directly within the patient's body and may offer a more durable and long-lasting therapeutic effect by inserting DNA into the patient's genome.
Gilead said it expects the transaction to reduce its adjusted per-share earnings by 23 cents to 25 cents this year.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.